Patient handout

LV non-compaction / hypertrabeculation cardiomyopathy (chronic)

PRODUCTION

1. Your condition

This handout is for lv non-compaction / hypertrabeculation cardiomyopathy (chronic). Your care team identified this based on: echo/cmr: prominent lv trabeculation, nc/c ratio above threshold.

Other reasons your team may use this plan: heart failure symptoms with hypertrabeculated lv; systemic embolism / stroke with hypertrabeculated lv; family history of lvnc / dcm / scd.

3. When to call your provider

Contact your care team if any of the following happen:

New systolic dysfunction → HFrEF pathway — 2022 ACC/AHA HF
Embolic event / LV thrombus → anticoagulation — 2023 ESC Cardiomyopathy
Sustained VT / heart pumping strength (LVEF) ≤35 on the four foundational heart-failure medications → ICD evaluation — 2023 ESC Cardiomyopathy

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

LVNC with reduced heart pumping strength (LVEF) — full HFrEF 4-pillar the four foundational heart-failure medications applies (unlike amyloid) — 2022 ACC/AHA HF
Prior systemic embolism / documented LV thrombus / AF / reduced EF — anticoagulate — 2023 ESC Cardiomyopathy
Sustained VT/VF, heart pumping strength (LVEF) ≤35 on the four foundational heart-failure medications, or high-risk arrhythmic genotype/family — ICD evaluation — 2023 ESC Cardiomyopathy
Pregnancy with LVNC-cardiomyopathy — peripartum decompensation risk if systolic dysfunction; pregnancy-safe regimen (BB ± hydralazine; stop ACEi/ARNi/SGLT2i); cardio-obstetric — ESC 2018 Pregnancy

5. Follow-up

Family cascade screening (familial); avoid lifelong over-surveillance of benign hypertrabeculation

6. Sources

Guideline: 2023 ESC Cardiomyopathy Guideline + 2022 AHA/ACC/HFSA HF Guideline; Petersen/Jenni imaging criteria